Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W FRY

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Biochemical Pharmacology|April 1, 1985
Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide)T J Boritzki, D A Berry, J A Besserer, et al.
Cancer Research|September 1, 1991
In vivo and in vitro evaluation of the alkylating agent carmethizoleW L Elliott, D W Fry, W K Anderson, et al.
Advances in Enzyme Regulation|January 1, 1987
Biochemical pharmacology and experimental chemotherapy studies with guanine-7-oxide, a novel purine antibioticR C Jackson, T J Boritzki, J A Besserer, et al.
Biochemical Pharmacology|November 14, 1997
Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitorD W Fry, J M Nelson, V Slintak, et al.
Science (New York, N.Y.)|August 19, 1994
A specific inhibitor of the epidermal growth factor receptor tyrosine kinaseD W Fry, A J Kraker, A McMichael, et al.
Cancer Research|September 15, 2000
Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injuryS R Ritland, S J Gendler, L J Burgart, et al.
Journal of Medicinal Chemistry|January 5, 1996
Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptorA J Bridges, H Zhou, D R Cody, et al.
Journal of Medicinal Chemistry|April 26, 1996
Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A M Thompson, et al.
The Journal of Biological Chemistry|March 30, 2001
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6D W Fry, D C Bedford, P H Harvey, et al.
Journal of Medicinal Chemistry|January 6, 1995
Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinasesB D Palmer, G W Rewcastle, A M Thompson, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Biochemical Pharmacology|April 1, 1985
Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide)T J Boritzki, D A Berry, J A Besserer, et al.
Cancer Research|September 1, 1991
In vivo and in vitro evaluation of the alkylating agent carmethizoleW L Elliott, D W Fry, W K Anderson, et al.
Advances in Enzyme Regulation|January 1, 1987
Biochemical pharmacology and experimental chemotherapy studies with guanine-7-oxide, a novel purine antibioticR C Jackson, T J Boritzki, J A Besserer, et al.
Biochemical Pharmacology|November 14, 1997
Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitorD W Fry, J M Nelson, V Slintak, et al.
Science (New York, N.Y.)|August 19, 1994
A specific inhibitor of the epidermal growth factor receptor tyrosine kinaseD W Fry, A J Kraker, A McMichael, et al.
Cancer Research|September 15, 2000
Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injuryS R Ritland, S J Gendler, L J Burgart, et al.
Journal of Medicinal Chemistry|January 5, 1996
Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptorA J Bridges, H Zhou, D R Cody, et al.
Journal of Medicinal Chemistry|April 26, 1996
Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A M Thompson, et al.
The Journal of Biological Chemistry|March 30, 2001
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6D W Fry, D C Bedford, P H Harvey, et al.
Journal of Medicinal Chemistry|January 6, 1995
Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinasesB D Palmer, G W Rewcastle, A M Thompson, et al.
Pageof 9